Trial Profile
An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs Arfolitixorin (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Isofol Medical
- 17 Jan 2021 Results (n=81) evalauting biomarkers of arfolitixorin/5-FU-based treatment in relation to safety and response in metastatic colorectal cancer, presented at the 2021 Gastrointestinal Cancers Symposium
- 15 Jan 2021 According to an Isofol Medical media release, gene expression results from the study will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) 2021.
- 30 Sep 2020 Results (n=31) from the extension cohort are presented in an Isofol Medical media release.